Wilms tumor protein 1 (WT1) is a transcription factor overexpressed in several types of leukemia and solid tumors. For this reason, WT1 is an attractive target for immunotherapy. Four peptide nonamers from WT1 have been identified by others to generate a WT1-specific cytotoxic response in the context of human leukocyte antigen (HLA)-A0201 and A2402. However, as WT1 is a self-antigen, breaking tolerance is a potential obstacle to vaccination. Here, we use a strategy to circumvent tolerance by designing synthetic immunogenic analog peptides that could crossreact to the native peptides (a heteroclitic response). A number of synthetic peptides derived from nonamer sequences of the WT1 protein were designed in which single amino-acid substitutions were introduced at HLA-A0201 major histocompatibility complex (MHC)-binding positions. Several of new peptides could stabilize MHC class I A0201 molecules better than native sequences. Some analogs were also able to elicit WT1-specific T-cell recognition and cytotoxic T-cell lymphocytes more effectively than native sequences. Importantly, T cells stimulated with the new analogs crossreacted with the native WT1 peptide sequence and were able to kill HLA-matched chronic myeloid leukemia cell lines. In conclusion, analog heteroclitic WT1 peptides with increased immunogenicity can be synthesized and are potential cancer vaccine candidates.
Introduction
Wilms tumor protein 1 (WT1) is a zinc-finger transcription factor expressed during normal ontogenesis (fetal kidney, testis and ovary). [1] [2] [3] In adults, WT1 expression is limited to low levels in the nuclei of normal CD34 þ hematopoietic stem cells, myoepithelial progenitor cells, renal podocytes and some cells in testis and ovary. [4] [5] [6] The WT1 gene is overexpressed in acute and chronic myelogenous leukemia and myelodysplastic syndromes. [7] [8] [9] Solid tumors such as breast, lung, thyroid, testicular and ovarian carcinomas and melanomas also express the WT1 gene. 10 The WT1 gene seems to be involved in the process of leukemogenesis and its expression may be essential to maintain the uncontrolled proliferation and defective differentiation of leukemic cells. 11, 12 Thus, WT1 is an attractive target for immunotherapy.
WT1-specific antibodies directed against the N-terminus portion of the WT1 protein were found in the sera of 15-30% of patients with acute myeloid leukemia (AML), but in only 2% of healthy donors. 13, 14 This implies that WT1-specific CD4T helper responses should be present in these patients. WT1 class II peptide candidates specific for human leukocyte antigen (HLA) DRB1*0401, DP-5 and DR53 (DRB4*0101) have been identified. [15] [16] [17] [18] In addition, class I immunogenic peptides derived from WT1 protein have been described. At least four peptide nonamers from WT1 have been identified by others to generate a WT1-specific cytotoxic response in the context of HLA-A0201 and A2402. T-cell lines or T-cell clones expanded from single healthy donors, but not from patients with leukemias, were able to lyse WT1 þ , HLA-A0201 þ or 2402 þ leukemic cell lines and in some cases, blast cells from HLA-matched patients with AML or acute lymphoblastic leukemia (ALL). [19] [20] [21] [22] [23] [24] Animal models also have been used to show the immunogenicity of WT1 protein. Mice immunized with either the WT1 peptide or DNA encoding WT1 elicited specific cytotoxic T lymphocytes (CTL) and rejected a challenge from WT1-expressing tumor cells. 25, 26 Importantly, histopathologic studies performed in immunized animals did not show any evidence of autoimmunity. Finally, nonobese diabetic-severe combined immunodeficient (NOD-SCID) mouse models have been used to demonstrate the activity of human T-cell lines or clones in the eradication of clonogenic cells capable of transferring leukemia. 24, 27 Immunological tolerance to self-proteins can prevent the development of immune responses to many self-cancer antigens. In the present study, we use a new strategy to circumvent tolerance by designing synthetic immunogenic analog peptides to generate T-cell responses that could crossreact with the native peptides (a heteroclitic response). We report the use of aminoacid substitutions at HLA-A0201-binding anchor positions in native nine-mer WT1 peptides to increase the binding affinity of the modified nine-mer WT1 peptides to HLA-A0201 major histocompatibility complex (MHC) molecules. These analog peptides could more efficiently induce WT1-specific HLA-A0201-restricted CTL than the natural nine-mer WT1 peptides.
Materials and methods

Synthetic peptides
Each of the peptides utilized in this study was purchased and synthesized by Genemed Synthesis Inc. (San Francisco, CA, USA) using fluorenylmethoxycarbonyl chemistry, solid phase synthesis and purified by high-pressure liquid chromatography. The quality of the peptides was assessed by high-performance liquid chromatography analysis, and the expected molecular weight was observed using matrix-assisted laser desorption mass spectrometry. Peptides were sterile and 70-90% pure. The peptides were dissolved in dimethyl sulfoxide (DMSO) and diluted in phosphate-buffered saline (PBS; pH 7.4) or saline to give a concentration of 5 mg/ml and were stored at À801C.
The amino-acid sequences and predicted score for binding to HLA-A0201, generated by two online available databases (BIMAS and SYFPEITHI), are shown (Table 1) . 28 For in vitro experiments, we also used an irrelevant control peptide, HLA-A24 consensus.
Cell lines
Cell lines were cultured in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 5% fetal calf serum (FCS), penicillin, streptomycin, 2 mM glutamine and 2-mercaptoethanol at 371C in humidifier air containing 5% CO 2 . LAMA81 is a cell line expressing b3a2 translocation, WT1 positive and HLA-A0201, BV173 was established from peripheral blood of a male patient with chronic myeloid leukemia (CML) in blast crisis, b2a2, WT1 positive and HLA-A0201, cell line 697 was established from the bone marrow of a child with ALL, is e1a2, WT1 positive and HLA-A0201 (these cell lines were kindly provided by Hans J Stauss). SKLY-16 is a human B-cell lymphoma expressing HLA-A0201, but WT1 negative. T2 is an HLA-A0201 human cell line lacking TAP1 and TAP2 and therefore unable to present peptides derived from cytosolic proteins.
T2 assay for peptide binding and stabilization of HLA-A0201
T2 cells (TAPÀ, HLA-A0201 þ ) were incubated overnight at 27 or 371C at 1 Â 10 6 cells/ml in FCS-free RPMI medium supplemented with 5 mg/ml human b2m (Sigma, St Louis, MO, USA) in the absence (negative control) or presence of either a positive reference tyrosinase peptide or test peptides at various final concentrations (50, 10, 1 and 0.1 mg/ml). Following a 4-h incubation with 5 mg/ml brefeldin A (Sigma), T2 cells were labeled for 30 min at 41C with a saturating concentration of anti-HLA-A2.1 (BB7.2) mAb, then washed twice. The cells were then incubated for 30 min at 41C with a saturating concentration of fluorescein isothiocyanate-conjugated goat immunoglobulin (Ig)G F(ab 0 )2 anti-mouse Ig (Caltag, South San Francisco, CA, USA), washed twice, fixed in PBS/1% paraformaldehyde and analyzed using a FACS Calibur cytofluorometer (Becton Dickinson, Immunocytometry systems, San Jose, CA, USA).
The mean intensity of fluorescence (MIF) observed for each peptide concentration (after division of the MIF observed without peptide) was used as an estimate of peptide binding and expressed as a fluorescence index. Stabilization assays were performed similarly. Following initial evaluation of peptide binding at time 0, cells were washed in RPMI complete medium to remove free peptides and incubated in the continuous presence of 0.5 mg/ml brefeldin-A for 2, 4, 6 and 8 h. The amount of stable peptide-HLA-A0201 complexes was estimated as described above by indirect immunofluorescence analysis. The half-time of complexes is an estimate of the time required for a 50% reduction of the time 0 MIF value.
In vitro immunization and human T-cell cultures
After Institutional Research Board approved informed consent, peripheral blood mononuclear cells (PBMCs) from HLA-A0201-positive healthy donors were obtained by Ficoll-density centrifugation. Peripheral blood dendritic cells (DCs) were generated as follows: monocyte-enriched PBMC fractions were isolated, using a plastic adherence technique, from total PBMCs. The plastic-adherent cells were cultured further in RPMI 1640 medium supplemented with 1-5% autologous plasma, 1000 U/ ml recombinant human interleukin (IL)-4 (Shering-Plough, Kenilworth, NJ, USA) and 1000 U/ml recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (Immunex, Seattle, WA, USA). On days 2 and 4 of incubation, part of the medium was exchanged for fresh culture medium supplemented with IL-4 and GM-CSF, and culture was continued. On day 6, half of the medium was exchanged for culture medium supplemented with IL-4, GM-CSF and 10 ng/ml recombinant human tumor necrosis factor-a (R&D Systems, Minneapolis, MN, USA) and 500 ng/ml of trimeric soluble CD40L (Immunex, Seattle). On day 9, the cells were harvested and used as monocyte-derived DCs for antigen stimulation. The cells generated expressed DC-associated antigens, such as CD80, CD83, CD86, and HLA class I and class II on their cell surfaces (data not shown). T lymphocytes were isolated from the same donors using negative selection by depletion with an antiCD11b, anti-CD56 and CD19 MoAb (Miltenyi, CA, USA). A total of 1 Â 10 6 pure T lymphocytes were cultured with 1 Â 10 5 autologous DCs in RPMI 1640 medium supplemented with 5% heat-inactivated human autologous plasma with WT1 synthetic peptides at a concentration of 10 mg/ml and b2 microglobulin at 2 mg/ml in 24-well plates in the presence of 5-10 ng/ml recombinant human IL-7 (Genzyme) and 0.1 ng/ml of IL-12.
After culture for 3 days 20 U/ml of IL-2 was added. After 10 days, 1 Â 10 6 cells were stimulated again by adding 2 Â 10 5 autologous magnetically isolated CD14 þ monocytes together with 10 ng/ml of IL-7 and 20 U/ml of IL-2 and peptide at a concentration of 10 mg/ml. In some cases, after culture for another 7 days, the cells were stimulated a third time, in the same manner. After the second or third stimulation, interferon (IFN)-g secretion of these cells was then examined by ELISPOT. T cells were then again stimulated with autologous B cells expanded in the presence of CD40L and IL-4 or with autologous transformed EBV-B cell lines. After several additional stimulations, cells were tested for cytotoxicity using a Chromium-51 assay.
IFN-g ELISPOT
HA-Multiscreen plates (Millipore, Burlington, MA, USA) were coated with 100 ml of mouse anti-human IFN-g antibody (10 mg/ ml; clone 1-D1K, Mabtech, Sweden) in PBS, incubated overnight at 41C, washed with PBS to remove unbound antibody and blocked with RPMI/autologous plasma for 1 h at 371C. Purified CD8 þ T cells (more than 95% pure) were plated at a concentration of 1 Â 10 5 /well. T cells were stimulated with 1 Â 10 4 T2 cells per well pulsed with 10 mg/ml of b2-microglobulin (Sigma, St Louis, MO, USA) and either 50 mg/ml of test peptide positive control influenza matrix peptide, or irrelevant control peptide at a final volume of 100-200 ml/well. Control wells contained T2 cells with or without CD8 þ cells. Additional controls included medium or CD8 þ alone plus PBS/ 5% DMSO diluted according to the concentrations of peptides used for pulsing T2 cells. After incubation for 20 h at 371C, plates were extensively washed with PBS/0.05% Tween and 100 ml/well biotinylated detection antibody against human IFN-g (2 mg/ml; clone 7-B6-1, Mabtech, Sweden) was added. Plates were incubated for an additional 2 h at 371C and spot development was performed as described. 29 Spot numbers were automatically determined with the use of a computer-assisted video image analyzer with KS ELISPOT 4.0 software (Carl Zeiss Vision, Germany).
Chromium 51 cytotoxicity assay
The presence of specific CTLs was measured in a standard 4-h chromium release assay as follows: 4 Â 10 6 targets were labeled with 300 mCi of Na 2 51 CrO 4 (NEN Life Science Products Inc., Boston, MA, USA) for 1 h at 371C. After washing, cells at 2 Â 10 6 /ml were incubated with or without synthetic peptides at a concentration of 10 mg/ml for 2 h at 201C in the presence of b 2 -microglobulin at 3 mg/ml. After washing by centrifugation, target cells were resuspended in complete media at 5 Â 10 4 cells/ml and plated in a 96-well U-bottom plate (Becton Dickinson NY) at 5 Â 10 3 cells/well with effector cells at effector to target ratios (E/T) ranging from 100:1 to 10:1. Plates were incubated for 4 h at 371C in 5% CO 2 . Supernatant fluids were harvested and radioactivity was measured in a gamma counter. Percent specific lysis was determined from the following formula: 100 Â ((experimental releaseÀspontaneous release)/ (maximum releaseÀspontaneous release)). Maximum release was determined by lysis of targets in 2.5% Triton X-100.
Quantitative RT-PCR for WT-1 transcripts
Total RNA was isolated from the various cell lines using a phenol/chloroform extraction method. RNA purity was confirmed by absorbance at 260 nm. The reverse transcriptase (RT) reaction was adapted from protocols supplied by Applied Biosystems (Foster City, CA, USA). Beginning with 1 mg of total RNA, random hexamers and RT were used to isolate cDNA. For the polymerase chain reaction (PCR) reaction, cDNA was mixed with the following WT1 primers and probe: forward primer (located on exon 7): 5 0 -CAGGCTGCAATAAGAGATATTT TAAGCT-3 0 ; and reverse primer (located on exon 8): 5 0 -GAAGTCACACTGGTATGGTTTCTCA-3 0 ; Taqman probe (located on exon 7) 5 0 -CTTACAGATGCACAGCAGGAAGCA CACTG-3 0 . The fluorescent probe was labeled with 6-carboxyfluorscein phosphoramide (FAM) as repoter dye at the 5 0 -end and with the quencher dye carboxy-tetramethyl-rhodamine at the 3 0 -end (Integrated DNA Technologies, Coralville, IA, USA). The PCR reaction 30 began with a 2 min step at 501C to activate the UNG enzyme, followed by 10 min at 951C to inactivate the Table 1 . Fluorescence index is the ratio between the median fluorescence with the peptide tested divided by median fluorescence with no peptide. The X axis shows different concentrations per well of the peptide tested.
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Results
Identification and generation of peptides with a high probability to bind to HLA-A0201
Peptides potentially reactive with CTL can be predicted by means of a peptide library-based scoring system for MHC class I-binding peptides. Amino-acid sequences of the full human WT-1 protein were scanned for peptides with a potential binding capacity for HLA-A0201 (about 40% of the Caucasian population). By using the software of the Bioinformatics and Molecular Analysis Section (National Institutes of Health, Washington, DC, USA) available at http://bimas.dcrt.nih.gov/ cgi-bin/molbio/ ken_parker_comboform, which ranks nine-mer peptides on a predicted half-time dissociation coefficient from common HLA class I molecules, we initially selected four peptides (A, B, C and D) from the WT1 protein with comparatively high binding scores for HLA-A0201. A second set of five peptides (E, F, G, H and J) was selected with lower binding scores with the idea of choosing peptides with less probability of having their T-cell receptors (TCRs) deleted peripherally by thymic selection. In six out of nine peptides derived from HLA-A0201, which had already preferred residues at position two and nine (primary anchor motifs), we looked in silico for further improvement in the ability of these peptides to bind to HLA-A0201 molecules. Previous studies have shown that modification of the secondary anchor motif at position one by an aromatic amino acid, tyrosine (Y), substitution increases the binding and affinity of the peptides. 31, 32 After this alteration, the computer algorithm predicted half-lives up to 70 times that of the native peptide sequence for the six peptides ( Table 1) . The other three peptides derived from the prediction of binding to HLA-0201 molecules were improved by a single acid substitution introduced at HLA-A0201 primary preferred residues, two of them by a leucine substitution at position two and one by valine substitutions at position nine. Once again, these changes improved the predicted half-life of the peptides up to thousand times that of the native sequence (Table 1) . 28 Binding of HLA-A0201 by selected peptides derived from WT1 protein
The immunogenicity of MHC class I-restricted peptides requires the capacity to bind and stabilize MHC class I molecules on the live cell surface. Moreover, the computer prediction models above have only 60-80% predictive accuracy; so we next sought direct measurement of the strength of the interaction between the peptides and the HLA-A0201 molecules using a conventional binding and stabilization assay that uses the antigen-transporting-deficient (TAP2 negative) HLA-A0201 human T2 cells. T2 cells lack TAP function and consequently are defective in properly loading class I molecules with antigenic peptides generated in the cytosol. The association of exogenously added peptides with thermolabile, empty HLA-A0201 molecules stabilizes them and results in an increase in the level of surface HLA-A0201 recognizable by specific anti-HLA-A0201 mAb such as BB7.2.
The first set of peptides was analyzed (Figure 1 ). These four peptides had well-recognized binding motifs and a tyrosine Table 1 . Fluorescence index is the ratio between the median fluorescence with the peptide tested divided by median fluorescence with no peptide. The X axis represents different concentrations per well of the peptide tested.
Improved human T-cell responses against synthetic HLA-0201 analog peptides J Pinilla-Ibarz et al substitution in position one was introduced to increase the stability of the peptides in the HLA groove. Three of the native peptides (A, B and D) from which the analogs were derived have been shown to be immunogenic by other groups. 20, 23 For peptides B and D, the amino-acid substitution (sequences B1 and D1) improved the measured binding of the peptide to the HLA-0201 molecules. For peptide A, a well-recognized immunogenic peptide, 21 the analog peptide showed similar behavior in the binding assay. The peptide C analog showed worse binding ability after the tyrosine substitution.
A second set of five pairs of peptides was evaluated in which the native peptides had lower binding predictions. These peptides were chosen based on the rationale that the reactive T cells may not have been deleted from the peripheral TCR repertoire. As expected, it was far easier to improve these peptides of initial poor affinity. Only one of the native peptides (J) from which the analog was derived had been shown to be immunogenic by others. 23 The tyrosine substitution improved the binding of the synthetic peptide E1. Peptide F1, an analog with demonstrated immunogenicity (see below), was predicted to have no better binding than the native sequence by BIMAS analysis and somewhat better binding by SYFPEITHI.
In the in vitro binding assay, the new synthetic peptide (F1) did not show any improvement. Peptides G and H had poor predicted binding. After substitutions of a lysine in position two for peptide G and a valine in position nine for peptide H, the new synthetic peptides G1 and H1 improved their predicted binding 500-1000 times. These modifications corresponded with an improved binding in the in vitro T2 assay. Finally, peptide J, the only peptide known to be immunogenic in the second group of peptides, 23 was predicted to be improved further by a tyrosine substitution in position one. However, the binding assay demonstrated the change to be deleterious and peptide J1 had a lower binding than its native pair (Figure 2 ).
Early and more potent induction of CD8 immune response against new synthetic peptides detected by IFN-g assay Although affinity for MHC molecules is necessary for peptide immunogenicity, there is also a requirement for presence of reactive precursor T cells with appropriate TCRs. Using an optimized T-cell expansion system, with monocyte-derived DC, Improved human T-cell responses against synthetic HLA-0201 analog peptides J Pinilla-Ibarz et al CD14 þ antigen presenting cells, and purified CD3 þ T cells, we investigated whether the new synthetic WT1 analogs could stimulate peptide-specific CTLs. Ten healthy HLA-A0201 donors were studied.
After two or three in vitro stimulations, cells of individuals responded, generating T cells that secreted IFN-g when challenged with different peptide-pulsed T2 cells as targets. Peptides A1, B1, C1, H1 and J1 revealed the best profiles. When compared with native peptides, these sequences were able to generate a better response, which was up to 100 times larger in some donors. The spot numbers were consistently higher with peptides that bound with higher affinity to HLA-A0201 molecules, as determined by the T2 assay. More importantly, T cells generated in the presence of the new synthetic analogs were able to recognize the native sequences. T cells stimulated with mutant sequences WT1A1, -B1, -H1 and -J1 were able to stimulate T cells to recognize their respective native sequences with a similar level of response (Figure 3 ). Peptide WT1A, the native sequence from WT1A1, is a well-recognized HLA-A0201-binding peptide described in the literature to have immunogenic properties in autologous and allogenic systems and there is indirect evidence that it can be naturally expressed on the surface of leukemic blasts. 24 After only two rounds of stimulations, WT1A1 was able to generate a robust immune response, whereas the WT1A native sequence was still near the limit of detection by the sensitive IFN-g ELISPOT technique. The WT1-C1 sequence also generated a strong immune response but did not crossreact with the native sequence. In some donors, WT1A, -C and -D native sequences were able to generate an immune response, but not comparable with the mutant sequence. No immune response could be generated against the D1 and E1 peptides, despite attempts using different donors.
Analog peptides derived from WT1 sequence kill pulsed targets cell as well as leukemic cell lines
Positive results in an IFN-g ELISPOT assay are not always associated with functional killing. Therefore, we tested the T-cell lines, and in some cases T-cell clones, obtained after multiple stimulations with the analog peptide in a chromium-51 release assay using peptide-pulsed target cell lines. T cells generated in vitro in the presence of WT1A1, -B1, -F1, -G1 and -J1 were able to kill T2 cells pulsed with specific peptides, but not T2 cells without peptide or T2 cells pulsed with a control peptide. Therefore, these peptides were able to generate a cytolytic response by cytotoxic T cells. Importantly, T cells stimulated with these mutant peptides were able to recognize the native sequences, confirming the necessary heteroclitic response (Figure 4) . Peptide F1 generated positive cytotoxicity with pulsed target cells with some donors, but not others. Experiments were also performed using HLA-matched CML cell lines expressing WT1 protein as targets ( Figure 5 ). We were only Improved human T-cell responses against synthetic HLA-0201 analog peptides J Pinilla-Ibarz et al able to generate T-cell-mediated specific cytotoxicity when using T cells stimulated with peptides WT1A1 ( Figure 5 ). This raises the possibility that the different native peptides were differently processed from the full-length WT1 protein or not sufficiently expressed on the surface of the leukemic cells, as has been postulated by others. Considerable differences in WT1 expression were confirmed in the cell lines by RT-PCR ( Figure 6 ). The cytotoxicity against HLA-matched CML blasts from patient samples was low (range ¼ 10-30%) with some donors and not significantly different from controls.
Discussion
The WT1 gene was initially defined as a tumor suppressor gene, but much evidence suggests that in leukemias this gene behaves more as an oncogene rather than a tumor suppressor gene. 33, 34 The overexpression of WT1 in leukemias and various solid tumors, the growth inhibition by WT1 antisense oligomers and the promotion of growth in hematopoietic progenitors cells transfected with the wild-type WT1 gene are strong arguments for its oncogenic function. 35, 36 The selective expression of WT1 in adult tissues also makes WT1 an excellent target for immunotherapy.
Immunological tolerance to self-protein can prevent the development of immune responses to many cancer selfantigens. Recent reports have shown low, but detectable frequencies of WT1 IFN-g-secreting T cells in peripheral blood of 50% of patients with AML. 37 Other groups using a more sensitive method were able to detect IFN-g mRNA in T cells stimulated with WT1 peptides in more than 50% of healthy individuals and in 60% of patients with CML. 38, 39 WT1-specific HLA-A0201 tetramers were found in a high percentage of patients with CML and from a small group of healthy subjects. 40 However, only low-avidity CD8 þ T-cell responses were seen likely secondary to tolerance mechanisms. Furthermore, there is no evidence that the specific T cells detected were able to lyse leukemic blasts or normal cell in vivo. Therefore, the expression of WT1 in normal and tumor cells would be expected to cause partial or complete tolerance of high-avidity CTLs.
Although WT1-specific T cells can be generated in healthy donors, [19] [20] [21] [22] [23] [24] it is likely that peptide immunization of patients with large numbers of leukemia cells (100-1000 billion) each expressing high levels of WT1 protein would be difficult. However, a successful phase I trial with an HLA-A2402 WT1 peptide vaccination in leukemias, myelodysplastic syndromes, lung and breast cancer has been recently published. 41 The Improved human T-cell responses against synthetic HLA-0201 analog peptides J Pinilla-Ibarz et al has been reported. 42 Larger trials are necessary to confirm these observations.
In this paper, we described a way to bypass tolerance creating several new synthetic analog peptides derived from native sequences from WT1 protein. Furthermore, we showed that these peptides were able to generate a stronger immune response as measured by IFN-g ELISPOT assay. Some of the new sequences generated cytotoxic responses and crossreacted against the native sequences. Finally, in some cases, the synthetic peptides described were able to recognize naturally presented WT1 peptides on the surface of the leukemia cell lines. We have generated these potent immunogenic sequences based on epitopes already described by others (A1, B1 and J1). 20, 23 In addition, we described new peptides not previously recognized (C1, F1 and G1). However, direct cytotoxicity against CML cell lines was only shown with the A1 (Figure 5 ) and F1 peptides. High levels of direct cytotoxicity on fresh CML blasts were difficult to demonstrate. This reduced activity against fresh blasts may be due to the lower expression of WT1 by the target cells, to the heterogeneity of the CD34 þ blast populations in the preparations or to inefficient processing of WT1. Other groups using high-avidity CTLs only were able to kill fresh leukemic blasts at low level, arguing that only a subpopulation of CD34 þ leukemic cells express adequate amounts of WT1 protein for cytolysis. 21 A correlation between antigenicity and MHC-binding affinity and/or stability of MHC-peptide complexes for class I epitopes has been demonstrated. Previous reports have demonstrated that peptides from viral-and tumor-derived proteins that bound with higher affinity to HLA class I molecules elicited stronger CTL immune responses than those that bound with lower affinity to these molecules. 43, 44 Enhancement of the antigenicity of epitopes with low to intermediate MHC affinity may therefore be achieved by improvement of their binding affinity and/or MHC/peptide complex stability, resulting in the induction of a strong CTL-specific response for the epitopes. [45] [46] [47] [48] Sugiyama's group 22 previously described a modified WT1A2401 peptide (methionine by tyrosine in position two) with better binding and immunogenic characteristics assessed by cytotoxicity. This peptide also has been tested in a phase I clinical trial, although no correlation was found between the use of the modified peptide and the clinical activity in comparison with the native peptide. 41 Stauss et al. circumvented the problem of tolerance by developing an allo-restricted CTL approach. T cells from HLA-A0201À donors are stimulated with HLA-A0201 þ APCs in the presence of peptides. This technique allowed the generation of high-avidity allo-restricted CTLs against an HLA-A0201 WT-1-derived peptide. The CTLs generated were able to specifically kill WT1 þ , HLA-A0201 þ leukemia cell lines and blasts. The high-avidity CTL eliminated the progenitors of CFU-GM and BFU-GM from CD34 þ CML samples, whereas lowavidity CTL had no effect. In an LTC-IC assay, the authors also showed the absence of inhibition of normal CD34 þ progenitors/stem cells. 21, 23 These T cells were able to selectively deplete clonogenic cells capable of transferring leukemia in NOD-SCID mice. 27 However, the isolation of peptide-specific allogenic CTL was unsuccessful in many donors, as allogenic stimulator cells often provoked dominant CTL responses against allogenic epitopes unrelated to the A2 peptide presented WT1 peptide. Unfortunately, this approach is difficult to apply clinically and the same authors have recently developed a method to transfect the specific TCR responsible for this response in autologous T lymphocytes for possible future clinical applications. 49 In conclusion, new heteroclitic peptides from the WT1 protein could offer alternative sequences for studies leading to clinical trials for vaccination of patients with myeloid malignancies.
